Leo Hansmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leo Hansmann has a total of 721 co-authors. Here are the top co-authors by number of shared publications:
- Carlotta Welters
Department of Hematology, Oncology, and Tumor Immunology, Charit e-Universit€ atsmedizin Berlin, Corporate Member of Freie Universit€ at Berlin and
32 shared publications - Amin Ben-Hamza
Department of Hematology, Oncology, and Tumor Immunology, Charit e-Universit€ atsmedizin Berlin, Corporate Member of Freie Universit€ at Berlin and
30 shared publications - Serena Stadler
Department of Pediatric Hematology and Oncology, Justus-Liebig University, Giessen, Germany
23 shared publications - Christine Damm-Welk
Department of Pediatric Hematology and Oncology, Justus-Liebig University, Giessen, Germany
22 shared publications - Rafael B. Blasco
Department of Pathology, Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts
22 shared publications - Roberto Chiarle
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
22 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7751-7766
Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis
Few treatment options remain for patients with large B-cell lymphoma progressing after multiple lines of therapy, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pretreated patients received lonca in the third and later lines of therapy. Seventy-six percent had received treatment with chimeric antigen receptor T cells (n = 55), bispecific antibodies (n = 56), or both (n = 40). The overall response rate was 27%, and complete response rate was 10%. Median progression-free survival (mPFS) and median overall survival (mOS) were 2.2 and 4.4 months, respectively. The mPFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥3 infections (in 13% of patients) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly longer than the remaining nonconsolidated patients (mOS: 15.2 vs 3.8 months; P = .048). In multivariable analysis, no response to the last therapy before lonca (OS: hazard ratio [HR], 2.5; P = .014) and secondary International Prognostic Index (PFS/OS: HR, ≥2.0; P ≤ .024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. Along with enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7751-7766
Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis
Few treatment options remain for patients with large B-cell lymphoma progressing after multiple lines of therapy, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pretreated patients received lonca in the third and later lines of therapy. Seventy-six percent had received treatment with chimeric antigen receptor T cells (n = 55), bispecific antibodies (n = 56), or both (n = 40). The overall response rate was 27%, and complete response rate was 10%. Median progression-free survival (mPFS) and median overall survival (mOS) were 2.2 and 4.4 months, respectively. The mPFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥3 infections (in 13% of patients) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly longer than the remaining nonconsolidated patients (mOS: 15.2 vs 3.8 months; P = .048). In multivariable analysis, no response to the last therapy before lonca (OS: hazard ratio [HR], 2.5; P = .014) and secondary International Prognostic Index (PFS/OS: HR, ≥2.0; P ≤ .024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. Along with enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Figure S2: Gating strategy for single cell sorting of patient 04 CD4+TCRab+ T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Figure S2: Gating strategy for single cell sorting of patient 04 CD4+TCRab+ T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 1: Characteristics of ALK+ALCL patients in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 1: Characteristics of ALK+ALCL patients in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 5: List of selected TCRs identified by single cell TCRab sequencing.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 5: List of selected TCRs identified by single cell TCRab sequencing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 6: Binding prediction of the NPM1::ALK fusion peptide to HLADRB13 alleles.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 6: Binding prediction of the NPM1::ALK fusion peptide to HLADRB13 alleles.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 4: Summary of the CD4 T cell responses to ALK in healthy donors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 4: Summary of the CD4 T cell responses to ALK in healthy donors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Figure S1: ALK-reactive CD4 T cells of patient 04 at diagnosis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Figure S1: ALK-reactive CD4 T cells of patient 04 at diagnosis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data File S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Data File S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data File S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Data File S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 3: Summary of the CD4 T cell responses to ALK in ALCL patients
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 3: Summary of the CD4 T cell responses to ALK in ALCL patients
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 2: List of NPM1::ALK peptide sequences and ALK pools
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood
Supplementary Table 2: List of NPM1::ALK peptide sequences and ALK pools